[ad_1]
Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL, 1 mL Single-Dose Vial is bioequivalent and medically equal to Pfizer Inc.’s Depo-Provera Injectable Suspension.
The product shall be out there within the third quarter of FY23. In line with IQVIA, the licensed product has a market measurement of roughly US$ 62 million for the interval ending June 2022.
That is the 147 ANDA (together with ten tentative approvals) obtained by Eugia Pharma Speciality Group (EPSG) services, which manufacture each oral and sterile specialty prescribed drugs.
At round closing, Aurobindo Pharma was buying and selling at Rs559.75 up by 0.03% from its earlier closing of Rs559.60 on the BSE.
For suggestions and recommendations, write to us at [email protected]
[ad_2]
Source link